Abstract
Antibody-drug conjugates (ADCs) take the advantage of antigen specificity of monoclonal antibodies to deliver highly potent cytotoxic drugs selectively to antigen-expressing tumor cells. The recent approval of Adcetris™ and Kadcyla™ as well as emerging data from numerous ongoing clinical trials underscore the role of ADCs as a new therapeutic option for cancer patients. However, conventional conjugation methods generally result in a heterogeneous mixture of ADCs, which can result in significant therapeutic liabilities and can lead to complicated manufacturing processes. The increased understanding from the clinical investigation of current ADCs and site-specific bioconjugation technologies has enabled scientists to accelerate the discovery and development of the next generation ADCs with defined and homogeneous composition. The present manuscript reviews the recent advances and trends in the research and development of novel ADCs obtained by site-specific conjugation method.
Keywords: Antibody-drug conjugates, ADCs, conjugation site, DAR, homogeneous ADCs, site specific conjugation.
Current Cancer Drug Targets
Title:Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs)
Volume: 16 Issue: 6
Author(s): Wenlong Gao, Jingxin Zhang, Jun Xiang, Lei Zhang, Chengbin Wu, Pradeep K. Dhal and Bo Chen
Affiliation:
Keywords: Antibody-drug conjugates, ADCs, conjugation site, DAR, homogeneous ADCs, site specific conjugation.
Abstract: Antibody-drug conjugates (ADCs) take the advantage of antigen specificity of monoclonal antibodies to deliver highly potent cytotoxic drugs selectively to antigen-expressing tumor cells. The recent approval of Adcetris™ and Kadcyla™ as well as emerging data from numerous ongoing clinical trials underscore the role of ADCs as a new therapeutic option for cancer patients. However, conventional conjugation methods generally result in a heterogeneous mixture of ADCs, which can result in significant therapeutic liabilities and can lead to complicated manufacturing processes. The increased understanding from the clinical investigation of current ADCs and site-specific bioconjugation technologies has enabled scientists to accelerate the discovery and development of the next generation ADCs with defined and homogeneous composition. The present manuscript reviews the recent advances and trends in the research and development of novel ADCs obtained by site-specific conjugation method.
Export Options
About this article
Cite this article as:
Gao Wenlong, Zhang Jingxin, Xiang Jun, Zhang Lei, Wu Chengbin, K. Dhal Pradeep and Chen Bo, Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs), Current Cancer Drug Targets 2016; 16 (6) . https://dx.doi.org/10.2174/1568009616666160512144715
DOI https://dx.doi.org/10.2174/1568009616666160512144715 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy Recent Advances in Anti-Survivin Treatments for Cancer
Current Medicinal Chemistry Tea (Camellia sinensis (L.)): A Putative Anticancer Agent in Bladder Carcinoma?
Anti-Cancer Agents in Medicinal Chemistry Intravesical Drug Delivery into the Bladder to Treat Cancers
Current Drug Delivery Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry Methionine-Derived Metabolites in Apoptosis: Therapeutic Opportunities for Inhibitors of their Metabolism in Chemoresistant Cancer Cells
Current Medicinal Chemistry Peripherally Located A431 Cells are More Sensitive to Cell Death Induced by Exogenous Oxidative Stress
Current Signal Transduction Therapy ATF4, an ER Stress and Hypoxia-Inducible Transcription Factor and its Potential Role in Hypoxia Tolerance and Tumorigenesis
Current Molecular Medicine Hypoxia Inducible Factor as a Cancer Drug Target
Current Cancer Drug Targets Anticancer Agents: Tumor Cell Growth Inhibitory Activity and Binary QSAR Analysis
Current Pharmaceutical Design 4-Aminoquinazoline Analogs: A Novel Class of Anticancer Agents
Mini-Reviews in Medicinal Chemistry Immunoconjugates for Cancer Targeting: A Review of Antibody-Drug Conjugates and Antibody-Functionalized Nanoparticles
Current Medicinal Chemistry Biosynthesis of Anti-Proliferative Gold Nanoparticles Using Endophytic Fusarium oxysporum Strain Isolated from Neem (A. indica) Leaves
Current Topics in Medicinal Chemistry Fluorescent Porphyrin with an Increased Uptake in Peripheral Blood Cell Subpopulations from Colon Cancer Patients
Medicinal Chemistry The Role of Protonation States in Ligand-Receptor Recognition and Binding
Current Pharmaceutical Design Polymeric Nanoparticles to Combat Squamous Cell Carcinomas in Patients with Dystrophic Epidermolysis Bullosa
Recent Patents on Nanomedicine Porous Microspheres of Casein/Amorphous Calcium Phosphate Nanocomposite: Room Temperature Synthesis and Application in Drug Delivery
Current Nanoscience Mucoadhesive Chitosan Derivatives as Novel Drug Carriers
Current Pharmaceutical Design A Review on Subcutaneous Veins Localization Using Imaging Techniques
Current Medical Imaging